SAFE INVESTING



Apollo Hospitals Enterprise Limited
Corporate Identity Number: L85110TN1979PLC008035
Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel. +91-44-28290956, Fax.+91-44-28290956
Email: investor.relations@apollohospitals.com, Website: www.apollohospitals.com



			Standalone	D					Co	Consolidated		
Particulars	Three months ended 30/09/2021	Preceding Three months ended 30/06/2021	Corresponding Three months ended 30/09/2020	Year to date figures for current period ended	Year to date figures for previous period ended 30/09/2020	Previous year ended 31/03/2021	Three months ended 30/09/2021	Preceding Three months ended 30/06/2021	Corresponding Three months ended 30/09/2020	Year to date figures for current period ended 30/09/2021	Year to date figures for previous period ended 30/09/2020	Previous year ended 31/03/2021
The state of the s			Ilpanditod	Illipandited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Onaudited	Onaudited	Oligadisca	O				2000	2 77 200	7 50 755	A 95 125	10.60.500
Total Income from Operations (net)	2,83,149	3,00,345	2,41,924	5,83,494	4,38,244	9,17,119	3,72,270	3,78,485	2,77,204	7,50,755	4,95,125	10,60,500
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	28,903	23,957	3,953	52,860	(14,639)	18,581	38,299	30,512	3,015	68,811	(23,686)	16,082
Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	28,903	23,283	3,844	52,186	(14,748)	17,672	38,299	59,923	6,560	98,222	(20,142)	22,147
Net profit / (Loss) for the period after tax (after Exceptional and Extraordinary items)	18,589	15,004	3,252	33,593	(11,659)	10,515	26,741	50,068	5,899	76,809	(16,727)	13,677
Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	18,081	15,044	2,824	33,125	(12,248)	9,957	25,965	50,295	5,549	76,261	(17,232)	15,210
Paid up Equity Share Capital (Face value of Rs.5/- each)						7,189						7,189
Other Equity						5,12,973						4,52,293
Earnings Per Share of Rs. 5/- each												1074
Basic	*12.93	*10.44	*2.34	*23.36	*(8.38)	7.51	*17.24	*34.03	*4.33	*51.26	*(10.63)	10.74
Diluted	*12.93	*10.44	*2.34	*23.36	*(8.38)	7.51	*17.24	*34.03	*4.33	*51.26	*(10.63)	10./4
Networth				5,43,816	3,69,465	5,14,380		10 - 10 Sept 1500				
Paid up Debt Capital				20,000	50,000	20,000		September 200	Color Mayor Pan			
Debenture Redeemption Reserve				5,000	12,500	5000			OT THE PERSON			
				600	600	600		F 60 10	Art St. Martin State		THE SAME TOTAL	STORES OF ST

- 1. The above is an extract of the detailed format of financial results (both standalone and consolidated) for three and six months ended September 30.2021 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www. nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.
- The unaudited financial results (Standalone and Consolidated) of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2021 have been reviewed by the Audit Con Board of Directors of the Company at their meetings held on November 11, 2021 and November 12, 2021, respectively and have been subjected to limited review by the statutory auditors. and approved by the
- are Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL
- For the items referred in the Regulation 52(4) of the SEBI (Listing and Other Disclosu (www.bseindia.com and www.nseindia.com)
- 5. The Company has received approval from the Regional Director, Ministry of Corporate Affairs on June 28, 2021 for the Scheme of Amalgamation with the following wholly owned subsidiary companies, with the Appointed Date being April 1, 2020: The listed non-convertible debentures of the Company aggregating to Rs. 20,000 lakhs as on September 30, 2021 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.

a. Apollo Home Healthcare (India) Limited and b. Western Hospitals Corporation Private Limited

Consequent to giving effect to the said Scheme of Amalgamation, the Company has created a provision against loan of Rs. 674 lakhs extended by Western Hospitals Corporation Pr. Limited, a subsidiary, due to its adverse business conditions. This provision has been disclosed under Exceptional Items in this standalone financial results. lier years, to Apollo Lavasa

- The Board of Directors and the shareholders have approved in their meeting held on Juné 23, 2021, and August 14, 2021 respectively, a re-organisation through a slump sale of identified business undertaking comprising of the pharmacy distribution business including the online technology platform Apollo 24/7 and the Company's shareholding on Apollo Medicals Private Limited (AMPL) (an associate) to Apollo HealthCo Limited, a wholly owned subsidiary of the Company for a consideration of Rs.1,21,000 lakhs, subject to certain conditions precedent including receipt of requisite approvals from AMPL shareholders and secured creditors. Pending completion of the other conditions precedent to consummate the said transaction, the identified business undertaking is not available for immediate sale as prescribed under Ind AS 105, "Non-current Assets Held for Sale and Discontinued Operations" and consequently no effect for this transfer has been recorded in this standalone financial results.
- The front-end retail pharmacy business included in the standalone pharmacy segment ("divestment business") was transferred to Apollo Pharmacies Limited, pursuant to a Scheme of Arrangement, which was effective from September 1, 2020. The Company thereafter has identified Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, Fast Moving Consumer Goods (FMCG) and private label products.

sently, the figures for the three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months ended September 30, 2021 are not comparable with the figures for the previous three and six months are not comparable to the previous three six months are not considered and six months are not comparable to the six mon er 30, 2020 respectively.

Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs.

The utilisation of the QIP Issue proceeds upto September 30, 2021 is as follows:

Particulars
Fees paid to Lead Managers
Fees paid to Lead Managers
Foreclosure of debts
Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited
Acquisition of equity stake in Mutual Funds pending deployment as on 30th September 2021

The Company completed the acquisition of an additional 50% stake held by Gleneagles Development Pte Limited (erstwhile joint venturer) in Apollo Multi Speciality Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), Kolkata on 22nd April 2021 for a consideration of Rs. 41,000 lakhs. Consequently, AMSHL became a wholly owned subsidiary of the Company and has been consolidated effective from 22nd April 2021. The figures for the three and six months ended September 30, 2021 are therefore not comparable with the figures for the, corresponding three and six months ended September 30, 2020 respectively and the figures for the previous year ended March 31, 2021.

The acquisition date fair value of the existing equity interest in AMSHL compared to its carrying amount resulted in a gain of Rs. 29,411 lakhs, which has been included under exceptional items. The impact of this gain on Earnings Per Share (EPS) for the three months ended June 30, 2021 and six months ended September 30, 2021 is Rs.20.45 per equity share of Rs.5 each (not annualised). The Company has completed the purchase price allocation based on the report certified by the independent valuer in respect of the identifiable assets acquired and liabilities assumed, resulting in a goodwill of Rs. 53,711 lakhs. The goodwill arising out of the acquisition is presented within the Healthcare segment.

The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honourable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.

for APOLLO HOSPITALS ENTERPRISE LIMITED

Place : Chennai Date : 12th November, 2021

DR. PRATHAP C REDDY

СН-СН

